v3.26.1
Segment Information
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Information

12. Segment Information

Operating segments are defined as components of an entity for which discrete financial information is available and regularly reviewed by the Chief Operating Decision Maker (“CODM”) to allocate resources and assess performance. The Company’s CODM is its Chief Executive Officer ("CEO"), and the Company manages its operations as a single operating segment focused on developing regenerative medicines to address unmet medical needs. The Company’s measure of segment profit or loss is net loss. The CODM manages and allocates resources to the operations of the Company on a total company basis. Managing and allocating resources on a consolidated basis enables the CEO to assess the overall level of resources available and how to best deploy these resources across functions, therapeutic areas and research and development projects that are in line with the Company’s long-term company-wide strategic goals. Consistent with this decision-making process, the CEO uses consolidated financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources, and setting incentive targets. Operating expenses are used to monitor budget versus actual results. All material long-lived assets of the Company are located in the United States and Company’s revenues are derived from the United States, The Bahamas and Israel. The total assets of the one reporting segment are disclosed on the condensed balance sheets as of June 30, 2026 and December 31, 2025.

The following table is representative of the significant expense categories regularly provided to the CODM when managing the Company’s single reportable segment (in thousands):

 

 

Three Months Ended
June 30,

 

 

2026

 

 

2025

 

Revenues(1)

 

$

287

 

 

$

316

 

Less:

 

 

 

 

 

 

Cost of revenues

 

 

105

 

 

 

170

 

R&D costs(2)

 

 

952

 

 

 

739

 

G&A costs(3)

 

 

1,904

 

 

 

1,387

 

Personnel costs(4)

 

 

3,065

 

 

 

2,961

 

Other segment items(5)

 

 

334

 

 

 

87

 

Net loss

 

$

(6,073

)

 

$

(5,028

)

 

 

Six Months Ended
June 30,

 

 

2026

 

 

2025

 

Revenues(1)

 

$

685

 

 

$

697

 

Less:

 

 

 

 

 

 

Cost of revenues

 

 

239

 

 

 

276

 

R&D costs(2)

 

 

1,524

 

 

 

1,225

 

G&A costs(3)

 

 

3,589

 

 

 

2,788

 

Personnel costs(4)

 

 

5,503

 

 

 

5,983

 

Other segment items(5)

 

 

639

 

 

 

464

 

Net loss

 

$

(10,809

)

 

$

(10,039

)

(1) Includes Contract Manufacturing and Clinical Trial revenue

(2) Includes Clinical Development, Research & Discovery, CMC

(3) Includes Executive, Finance, Legal, Business Operations

(4) Includes compensation, benefits and equity-based compensation

(5) Includes depreciation and amortization, (interest income) and other specific charges